Drew Hope

We're funding new research by Professor Greg Hannon and Dr Kirsty Sawicka at the University of Cambridge. They want to find ways to treat triple negative breast cancer cells that can resist standard chemotherapy and lead to recurrence. Greg discovered that some breast cancer cells have increased activity of a protein called NRF2. This makes them resistant to chemo, but it also increases the cancer cells’ need for nutrients called non-essential amino acids. The researchers are testing whether limiting the availability of non-essential amino acids could make these breast cancer cells more vulnerable to chemo. They’ll do this through both diet and by using a drug called L-asparginase, and they’ll carry out these experiments in mice. They'll then investigate how breast cancer cells have responded to each of these treatments, and whether they show signs of adapting to or resisting the treatments to continue growing. https://lnkd.in/ezsv7kcq

103

2 Comments

Are you interested in how we can speed up the #medicine development process? Our project with the University of Cambridge explores how #AI can help to achieve this aim. ⤵️ #PfizerUK

15

🌍 🌎 🌏 Cell and Gene Therapy (CGT) landscape 📈 "With complexity and risk associated with each stage of assay development, our Advanced Therapy Medicinal Products (ATMP) best practice guidance offers a practical and phase-appropriate validation tool to help your cell and gene therapy programme succeed. Our ATMP guidance includes: - Application of Flow Cytometry - Vector Copy Number - Characterisation of the Capsid Particle Population for rAAV products - T Cell and NK Cell Characterisation Assays" Exciting publication from Medicines and Healthcare products Regulatory Agency. Jacqueline Barry leads on some really exciting work 🔊 This particularly vindicates the continued importance of developing a talented workforce. Flow Cytometry, qPCR / ddPCR and ELISA are some of the key pieces of equipment for the above assays 🥇 Ideas or requirements for training anyone? 😎 Cell and Gene Therapy Catapult, Ryan Smith, #regulatory, #assays, #skills, #communitybuilding

6

The number of Black principal investigators applying for UK Research and Innovation funding halved in a single year, official data reveals https://lnkd.in/eYt8vcDZ The significantly lower comparative success rates of Black principal investigators (some of whom overcome so much to become academics within HE to begin with), on research council funded projects, suggests that we are somehow less capable of doing research - just as the degree award gap suggests that Black students are just not as capable as other students. In my in own case, I was hugely fortunate to have the opportunity to access UKRI funding as a Black principal investigator, through a very specific, targeted call that had “positive action” outcomes associated with it. I am an outlier and this does not “disprove” what we know to be true about how the funding system operates. As a sector, we are losing wonderful academics and researchers to a system that as well as operating policies, practices and policies that disproportionately impact on racially minoritised academics does not operate an ethics of care. That, is systemic racism. This article tells us the impact of that.

87

3 Comments

Latest webinar release in our series..... "An Introduction to Extractables and Leachables Testing" provides valuable insights into study design, regulatory compliance and risk based approaches....don't delay and download today! #Extractables #leachables #webinar #pharma #pharmaceuticaltesting #analyticaltesting #productsafety #element

25

Check out some of our #UKYoungAcademy members at The Royal Society Science 2040 conference today, actively shaping the future of UK science. We're part of discussions on what the UK science system should look like in 2040 and how to achieve it. From industry, and non-profits to universities, we're exploring the role of education, skills, and infrastructure in driving scientific progress. Saloni Krishnan, Aditee Mitra, Dr Sandeep Sandhu, FRSB, Dhruti Shah, Alina Patelli

33

1 Comment

Political trust in advanced democracies like the UK and Japan faces challenges, especially heightened by COVID-19. Prof Thomas Scotto from Glasgow’s UofG School of Social and Political Sciences, alongside colleagues from Japan, responded by developing a 'trust monitor'. This initiative, supported by the UK ESRC: Economic and Social Research Council (ESRC) and the Japan Society for the Promotion of Science (JSPS), aims to understand and address the erosion of political trust. Their monthly surveys track trust dynamics, including attitudes towards the COVID-19 crisis. Check out their findings and explore the data through TrustTracker: http://trusttracker.org/ #PoliticalTrust #Research #COVID19 #SocialScience

6

1 Comment

This latest episode was inspired by the upcoming biosecurity regulations in the USA. I did some research on the topic to provide information regarding China, USA, UK and the EU. I hope you will find it interesting. #clinicalresearch #genomicdata #biosecurity

1

With an average of 15 years experience, the BioAscent chemistry team excels on both #medicinalchemistry and #syntheticchemistry projects

11

Standalone Plain Language Summaries of peer-reviewed publications (PLSP) enable biopharma companies to meet PLS commitments even when the journal publishing the original article doesn't. Collaborative research conducted by Takeda and Oxford PharmaGenesis and presented by Hicham Naimy at #ISMPPAnnual2024 shows that: - Standalone PLSP are a growth area, with over half of all standalone PLSP published in the last year - A range of companies and publishers are producing standalone PLSP, commonly for phase 3 clinical trials of drugs in their approved indications - Relatively few PLSP currently involve patients as co-authors Congratulations to Hicham Naimy and his co-authors Harriet Smith, Bianca Carmo, Vicki Houle, David Peters, Matthew Reynolds, Anja Schmidt and Fran Young on this incredibly helpful research, which was selected for inclusion in the ISMPP poster tour. https://lnkd.in/eEP-My2p

105

2 Comments

What sets BRILLIANT apart as an Education Event? I spoke to Andrew Croydon of The Association of the British Pharmaceutical Industry (ABPI) and asked him about their reasons for being involved. 1. Motivation for Attending:  "We are excited to attend the BRILLIANT Early Years to Careers event because it provides a unique opportunity to connect with educators and extend our commitment to invest in education as an investment in the future ."   2. Hopes for Achievement:  "By participating in this event, we hope to inspire teachers with our broad STEM education resources, alongside insights into the pharmaceutical industry, to help teachers better inform and motivate their students about career opportunities in this field."   3. Benefits for Teachers:  "This event is a fantastic platform for teachers to gain a deeper understanding of an innovation-based industry, learning about the industry’s latest advancements and key initiatives, and discovering how to incorporate this knowledge into curricula to inspire the next generation."   4. Message to Teachers:  "We want teachers to know that our UK pharmaceutical sector is committed to pioneering new treatments and improving lives. We believe that by sharing our work and passion, we can help educators inspire students to pursue rewarding careers based on informed choices."   At BRILLIANT, we create a unique space where industry leaders and educators come together. This collaboration is vital for bridging the gap between current educational practices and future job market needs. Our goal is to prepare children for the jobs of tomorrow. By aligning educational strategies with industry demands, we ensure that students acquire the critical skills required in priority sectors. My message to other industry leaders ... Be part of it! www.brilliantfestival.com

16

1 Comment

Come and catch Brittany Wingham🌱, Kiran Sharma and myself at the Single Cell Biology conference at the Wellcome Sanger Institute today to discuss scaling your single cell research with the power of benchtop automation! #singlecell

35

Rapid, detailed cell analysis technology soon ready to assess the difference it can make to process insights and timelines

11

Many thanks to NIHR (National Institute for Health and Care Research) for naming the ATOMIC-Meso trial, run by Professor Peter Szlosarek, as of one the 10 greatest health-changing research studies to have taken place in the North Thames Clinical Research Network. The phase 3 clinical trial unveiled a breakthrough in the treatment of malignant pleural mesothelioma (MPM), a rare and often rapidly fatal form of cancer associated with exposure to asbestos and which has limited therapeutic options. The trial found that a combination treatment of traditional chemotherapy with a new drug, ADI-PEG20, increased the median survival of participants by 1.6 months, and quadrupled the survival at 36 months, compared to placebo-chemotherapy. The ATOMIC-meso trial was the culmination of 20 years of research at Queen Mary’s Barts Cancer Institute that began with Professor Szlosarek’s discovery that malignant mesothelioma cells lack a protein called ASS1, which enables cells to manufacture their own arginine. He and his team have since dedicated their efforts to using this knowledge to create an effective treatment for patients with MPM. Read more on the NIHR website: https://lnkd.in/eAjiF9za #mesothelioma #cancer #research

60

2 Comments

NICE already recommended Genedrive as the point-of-care test of choice in its draft guidance before clopidogrel administration in the management of Ischemic Stroke (IS) and Transient Ischaemic Attack (TIA) patients. Really great achievement outperforming the laboratory test with respect to accuracy! #diagnostics #pharmacogenetics #PGx #pointofcare #POCT #stroke #nhs

6

1 Comment

An article highlighting the UK approval of the first AKT inhibitor capivasertib as a treatment for breast cancer. This drug was developed by Astex Pharmaceuticals and AstraZeneca in a project where structural biology was key. The article also includes an overview on AKT inhibitors more generally, for example the clinical trials being run by Taiho Pharmaceutical Co., Ltd., and Laekna Therapeutics. #drugdiscovery #smallmolecule #kinase #structuralbiology #SBDD #FBDD #cancer #oncology

27

#BIO2024 is next week! Find us at the UK Pavilion and speak to us about how Quotient Sciences can accelerate your drug development needs in #drugsubstance, #formulationdevelopment, #drugproduct, and #clinical needs such as #ADME, #FIH, #RelativeBA, #DDI, etc. #smallmolecule #peptide #cdmo #cro #cmc #sandiego

26

💡 Want to understand the UK landscape and influence future #funding, #policy and #infrastructure in intracellular drug delivery? 💉 Calling on my UK network to participate in this online workshop on 14th May 2024 (10am-12pm) if you have an interest in advancing innovation in intracellular drug delivery. Our Intracellular Drug Delivery Centre is making great progress, but we want to find out what we need to do next to support the sector and have teamed up with Innovate UK and Innovate UK Business Connect to help find out! ❓ Who should attend? Representatives from industry, academia and supporting organisations working in this space. You might be a drug developer with specific delivery needs that current approaches can’t meet, or working to develop new technologies that provide advantages over current technologies. We aim to understand the breadth of innovative technologies being developed in the UK and identify those which have potential to address current clinical and commercial challenges. ❓ Why attend? ✔ Ensure that the barriers and challenges that you as an individual or organisation are facing are considered in future funding and policy decisions. ✔ Enhance your understanding of current intracellular drug delivery landscape, unmet needs and opportunities. ✔ Hear from others working in the space. ✔ Find out about public infrastructure that can support your technology or drug development. Sign up here 🔗 https://lnkd.in/eQUvp5-A Yvonne Perrie MBE Sarah Brockbank Robin Shattock Neill Liptrott CPI Medicines Discovery Catapult Brendan Fish Dave Tudor Julie Anderson Emily Port Owen Burbidge Hareklea Markides Rachel Harris Sarah Goulding Mark Talford #Pharmaceutical #IntracellularDrugDelivery #NewTechnologies #DrugDelivery #LNP #mRNA #oligos #TMMCOP #oligonucleotides #LetsInnovateTogether #Innovation

58

9 Comments

Phase 1 oncology trials are essential to the progression of any clinical compound or device, but are often some of the most challenging trials for sites. This document outlines several considerations that sites should explore when considering Phase 1 oncology trials. Access it here ⇢ https://lnkd.in/ewCisQRQ

16